JP2017506630A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017506630A5 JP2017506630A5 JP2016550779A JP2016550779A JP2017506630A5 JP 2017506630 A5 JP2017506630 A5 JP 2017506630A5 JP 2016550779 A JP2016550779 A JP 2016550779A JP 2016550779 A JP2016550779 A JP 2016550779A JP 2017506630 A5 JP2017506630 A5 JP 2017506630A5
- Authority
- JP
- Japan
- Prior art keywords
- complex
- seq
- amino acid
- group
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000006850 spacer group Chemical group 0.000 claims 7
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 6
- 238000006467 substitution reaction Methods 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 125000005647 linker group Chemical group 0.000 claims 5
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 102000004503 Perforin Human genes 0.000 claims 3
- 108010056995 Perforin Proteins 0.000 claims 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000004968 inflammatory condition Effects 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 claims 1
- 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 229940028652 abraxane Drugs 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- -1 bevacizumab Chemical compound 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000002131 composite material Substances 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 125000004663 dialkyl amino group Chemical group 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229960004130 itraconazole Drugs 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1402006.9 | 2014-02-06 | ||
| GB201402006A GB201402006D0 (en) | 2014-02-06 | 2014-02-06 | Antibody-drug conjugates and immunotoxins |
| PCT/EP2015/052341 WO2015118030A2 (en) | 2014-02-06 | 2015-02-04 | Antibody-drug conjugates and immunotoxins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017506630A JP2017506630A (ja) | 2017-03-09 |
| JP2017506630A5 true JP2017506630A5 (enExample) | 2018-03-15 |
| JP6619743B2 JP6619743B2 (ja) | 2019-12-11 |
Family
ID=50390517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016550779A Active JP6619743B2 (ja) | 2014-02-06 | 2015-02-04 | 抗体−薬物複合体及び免疫毒素 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US10137202B2 (enExample) |
| EP (1) | EP3102244B1 (enExample) |
| JP (1) | JP6619743B2 (enExample) |
| KR (1) | KR102342935B1 (enExample) |
| CN (1) | CN105979971B (enExample) |
| AU (1) | AU2015215015B2 (enExample) |
| CA (1) | CA2937455C (enExample) |
| DK (1) | DK3102244T3 (enExample) |
| ES (1) | ES2788864T3 (enExample) |
| GB (1) | GB201402006D0 (enExample) |
| HU (1) | HUE049291T2 (enExample) |
| MX (1) | MX375383B (enExample) |
| PL (1) | PL3102244T3 (enExample) |
| PT (1) | PT3102244T (enExample) |
| SI (1) | SI3102244T1 (enExample) |
| WO (1) | WO2015118030A2 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201402006D0 (en) * | 2014-02-06 | 2014-03-26 | Oncomatryx Biopharma S L | Antibody-drug conjugates and immunotoxins |
| US11419934B2 (en) | 2015-08-18 | 2022-08-23 | Oncotelic Therapeutics, Inc. | Use of VDAS to enhance immunomodulating therapies against tumors |
| TWI852735B (zh) | 2015-12-04 | 2024-08-11 | 美商思進公司 | 四級胺化妥布賴森(tubulysin)化合物之結合物 |
| US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
| MX2020012273A (es) * | 2018-05-16 | 2021-04-28 | Dragonfly Therapeutics Inc | Proteína de union a nkg2d, cd16 y proteína de activación de fibroblastos. |
| EP3997104A1 (en) | 2019-07-08 | 2022-05-18 | 3B Pharmaceuticals GmbH | Compounds comprising a fibroblast activation protein ligand and use thereof |
| EP3763726A1 (en) | 2019-07-08 | 2021-01-13 | 3B Pharmaceuticals GmbH | Compounds comprising a fibroblast activation protein ligand and use thereof |
| WO2021005125A1 (en) | 2019-07-08 | 2021-01-14 | 3B Pharmaceuticals Gmbh | Compounds comprising a fibroblast activation protein ligand and use thereof |
| CN111499685A (zh) * | 2020-03-30 | 2020-08-07 | 联宁（苏州）生物制药有限公司 | 具有马来酰亚胺连接头的抗体偶联药物中间体及其合成方法 |
| CA3180665A1 (en) | 2020-05-19 | 2021-11-25 | Boehringer Ingelheim International Gmbh | Binding molecules for the treatment of cancer |
| CN116390937A (zh) | 2020-08-11 | 2023-07-04 | 治纳辅医药科技有限公司 | 一种包含il-12和抗cd20抗体的融合蛋白及其应用 |
| CA3192236A1 (en) | 2020-09-10 | 2022-03-17 | Tony Lahoutte | Antibody fragment against fap |
| JP2024500847A (ja) | 2020-12-18 | 2024-01-10 | センチュリー セラピューティクス，インコーポレイテッド | 適合可能な受容体特異性を有するキメラ抗原受容体システム |
| EP4274835A1 (en) | 2021-01-07 | 2023-11-15 | 3B Pharmaceuticals GmbH | Compounds comprising a fibroblast activation protein ligand and use thereof |
| EP4050018A1 (en) | 2021-01-07 | 2022-08-31 | 3B Pharmaceuticals GmbH | Compounds comprising a fibroblast activation protein ligand and use thereof |
| MX2024009564A (es) | 2022-02-11 | 2024-08-19 | Kanaph Therapeutics Inc | Composicion farmaceutica para tratamiento de cancer que comprende proteina de fusion que incluye il-12 y anticuerpo anti-fap, y uso de la misma. |
| WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
| AU2023264245A1 (en) | 2022-05-02 | 2024-12-19 | Precirix N.V. | Pre-targeting |
| KR20230162310A (ko) | 2022-05-20 | 2023-11-28 | 주식회사 카나프테라퓨틱스 | Light 단백질 및 항-fap 항체를 포함하는 융합단백질 및 이의 용도 |
| EP4311557A1 (en) | 2022-07-26 | 2024-01-31 | Oncomatryx Biopharma, S.L. | Fap-targeted antibody-drug conjugates |
| WO2025141153A1 (en) * | 2023-12-29 | 2025-07-03 | Oncomatryx Biopharma, S.L. | Endo180 targeted antibody-drug conjugates |
| EP4616869A1 (en) | 2024-03-15 | 2025-09-17 | Oncomatryx Biopharma, S.L. | Fap targeted antibody-drug conjugates |
| EP4684806A1 (en) | 2024-07-22 | 2026-01-28 | Oncomatryx Biopharma, S.L. | Fap-targeted antibody-drug conjugates |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4318752B2 (ja) | 1996-05-31 | 2009-08-26 | ヘルス・リサーチ・インコーポレーテッド | 抗エンドグリンモノクローナル抗体および抗血管新生治療におけるその使用 |
| EP0953639A1 (en) | 1998-04-30 | 1999-11-03 | Boehringer Ingelheim International GmbH | FAPalpha-specific antibody with improved producibility |
| US20020099180A1 (en) | 2000-03-17 | 2002-07-25 | Klaus Pfizenmaier | Human FAP-alpha-specific antibodies |
| EP1268550A2 (en) * | 2000-03-17 | 2003-01-02 | Boehringer Ingelheim Pharma KG | Human fap-alpha-specific antibodies |
| WO2005108419A1 (en) | 2004-05-07 | 2005-11-17 | Lea-Ann Kirkham | Mutant cholesterol-binding cytolysin proteins |
| US7517903B2 (en) | 2004-05-19 | 2009-04-14 | Medarex, Inc. | Cytotoxic compounds and conjugates |
| DE102005036542A1 (de) | 2005-08-03 | 2007-02-08 | Universität Stuttgart | CTL-Prodrug |
| EP1806365A1 (en) * | 2006-01-05 | 2007-07-11 | Boehringer Ingelheim International GmbH | Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them |
| NZ580132A (en) | 2007-03-14 | 2012-11-30 | Endocyte Inc | Binding ligand linked drug delivery conjugates of tubulysins to vitamins |
| EP2532673A3 (en) * | 2007-05-10 | 2014-01-08 | R & D Biopharmaceuticals Gmbh | Tubulysine derivatives |
| CN102339094A (zh) * | 2010-07-21 | 2012-02-01 | 英业达股份有限公司 | 服务器 |
| SG187746A1 (en) | 2010-08-13 | 2013-03-28 | Roche Glycart Ag | Anti-fap antibodies and methods of use |
| AU2012348017A1 (en) * | 2011-12-05 | 2014-07-03 | Igenica Biotherapeutics, Inc. | Antibody-drug conjugates and related compounds, compositions, and methods |
| EP3925627A1 (en) | 2012-05-15 | 2021-12-22 | Concortis Biosystems, Corp | Drug-conjugates and uses thereof |
| EP3210627B1 (en) * | 2012-07-12 | 2022-12-21 | Hangzhou Dac Biotech Co., Ltd | Conjugates of cell binding molecules with cytotoxic agents |
| ES2843537T3 (es) | 2014-01-28 | 2021-07-19 | Tube Pharmaceuticals Gmbh | Compuestos citotóxicos de tubulisina y conjugados de los mismos |
| GB201402006D0 (en) * | 2014-02-06 | 2014-03-26 | Oncomatryx Biopharma S L | Antibody-drug conjugates and immunotoxins |
-
2014
- 2014-02-06 GB GB201402006A patent/GB201402006D0/en not_active Ceased
-
2015
- 2015-02-04 HU HUE15705778A patent/HUE049291T2/hu unknown
- 2015-02-04 CN CN201580006995.5A patent/CN105979971B/zh active Active
- 2015-02-04 PL PL15705778T patent/PL3102244T3/pl unknown
- 2015-02-04 WO PCT/EP2015/052341 patent/WO2015118030A2/en not_active Ceased
- 2015-02-04 AU AU2015215015A patent/AU2015215015B2/en active Active
- 2015-02-04 ES ES15705778T patent/ES2788864T3/es active Active
- 2015-02-04 EP EP15705778.7A patent/EP3102244B1/en active Active
- 2015-02-04 CA CA2937455A patent/CA2937455C/en active Active
- 2015-02-04 JP JP2016550779A patent/JP6619743B2/ja active Active
- 2015-02-04 DK DK15705778.7T patent/DK3102244T3/da active
- 2015-02-04 US US15/116,430 patent/US10137202B2/en active Active
- 2015-02-04 KR KR1020167021198A patent/KR102342935B1/ko active Active
- 2015-02-04 PT PT157057787T patent/PT3102244T/pt unknown
- 2015-02-04 SI SI201531229T patent/SI3102244T1/sl unknown
- 2015-02-04 MX MX2016010127A patent/MX375383B/es active IP Right Grant
-
2018
- 2018-10-16 US US16/162,211 patent/US10864278B2/en active Active